BACKGROUND: Metformin improves insulin action, but feasibility in treating low milk supply is unknown. RESEARCH AIM: To determine the feasibility of a metformin- versus-placebo definitive randomized clinical trial in women with low milk production and signs of insulin resistance. METHODS: Pilot trial criteria included: Mother 1-8 weeks postpartum (ideally 1-2 weeks), low milk production, and ≥1 insulin resistance sign; and singleton, healthy, term infant. Eligible mothers were randomly assigned 2:1 (metformin:placebo) and instructed in frequent milk removal for 28 days with option to stop at 14 days. RESULTS: From 02/2015 through 06/2016, we screened 114 women, completed baseline assessments on 46, and trialed 15 (median, 36 days postpartum). Comparing metformin-assigned ( n = 10) to placebo ( n = 5), 70% versus 80% continued to day 28; peak median change in milk output was +8 versus -58 mL/24 hr ( p = .31) and 80% peaked at Day 14 for both groups; 0% versus 20% desired to continue assigned drug after study completion; 44% versus 0% reported nausea/vomiting. Post-hoc, median peak change in milk output was +22 (metformin completers, n = 8) versus -58 mL/24 hr (placebo + non-completers, n = 7, p = .07). At baseline assessment, median milk production was significantly lower in those with ( n = 31), versus those without ( n = 15) signs of insulin resistance ( p = .002). CONCLUSIONS: Although results trend toward hypothesized direction, trial feasibility concerns include late enrollment and only 20% of metformin-assigned participants sustaining improved milk output to Day 28, with none perceiving metformin worthwhile. Better tools are needed to identify and treat metabolically-driven low milk production. Registered at ClinicalTrials.gov (NCT02179788) on 02/JUL/2014.
BACKGROUND: Metformin improves insulin action, but feasibility in treating low milk supply is unknown. RESEARCH AIM: To determine the feasibility of a metformin- versus-placebo definitive randomized clinical trial in women with low milk production and signs of insulin resistance. METHODS: Pilot trial criteria included: Mother 1-8 weeks postpartum (ideally 1-2 weeks), low milk production, and ≥1 insulin resistance sign; and singleton, healthy, term infant. Eligible mothers were randomly assigned 2:1 (metformin:placebo) and instructed in frequent milk removal for 28 days with option to stop at 14 days. RESULTS: From 02/2015 through 06/2016, we screened 114 women, completed baseline assessments on 46, and trialed 15 (median, 36 days postpartum). Comparing metformin-assigned ( n = 10) to placebo ( n = 5), 70% versus 80% continued to day 28; peak median change in milk output was +8 versus -58 mL/24 hr ( p = .31) and 80% peaked at Day 14 for both groups; 0% versus 20% desired to continue assigned drug after study completion; 44% versus 0% reported nausea/vomiting. Post-hoc, median peak change in milk output was +22 (metformin completers, n = 8) versus -58 mL/24 hr (placebo + non-completers, n = 7, p = .07). At baseline assessment, median milk production was significantly lower in those with ( n = 31), versus those without ( n = 15) signs of insulin resistance ( p = .002). CONCLUSIONS: Although results trend toward hypothesized direction, trial feasibility concerns include late enrollment and only 20% of metformin-assigned participants sustaining improved milk output to Day 28, with none perceiving metformin worthwhile. Better tools are needed to identify and treat metabolically-driven low milk production. Registered at ClinicalTrials.gov (NCT02179788) on 02/JUL/2014.
Entities:
Keywords:
Breastfeeding; human milk production; insufficient milk; lactation; maternal health Randomized Controlled Trials
Authors: Juan Pablo Domecq; Gabriela Prutsky; Rebecca J Mullan; Vishnu Sundaresh; Amy T Wang; Patricia J Erwin; Corrine Welt; David Ehrmann; Victor M Montori; Mohammad Hassan Murad Journal: J Clin Endocrinol Metab Date: 2013-10-03 Impact factor: 5.958
Authors: K L Gatford; C M Houda; Z X Lu; S Coat; P A Baghurst; J A Owens; K Sikaris; J A Rowan; W M Hague Journal: Diabetes Obes Metab Date: 2013-02-28 Impact factor: 6.577
Authors: Margaret C Neville; Patricia Webb; Palaniappan Ramanathan; Meridee P Mannino; Chiara Pecorini; Jenifer Monks; Steven M Anderson; Paul MacLean Journal: Am J Physiol Endocrinol Metab Date: 2013-08-27 Impact factor: 4.310
Authors: Laurie A Nommsen-Rivers; Erin A Wagner; Dayna M Roznowski; Sarah W Riddle; Laura P Ward; Amy Thompson Journal: Breastfeed Med Date: 2022-04-26 Impact factor: 2.335